
OS Therapies Inc — Investor Relations & Filings
OS Therapies Inc. is a clinical-stage cancer immunotherapy company focused on developing treatments for cancers that express the HER2 protein. The company's approach is to activate the patient's immune system to target and destroy tumor cells. Its lead candidate, OST-HER2, is a therapeutic vaccine initially being developed for osteosarcoma, a type of bone cancer with a significant unmet medical need. The company plans to expand the development of its technology to other HER2-positive solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers. The pipeline also includes proprietary technologies like OST-tADC Tunable Drug Conjugates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-18 | English | |
| 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46383305 | QUARTERLY REPORT | 2026-05-18 | English | ||
| 33196663 | 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | ||
| 32898412 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898413 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898414 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898415 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898416 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898417 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898418 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 31749726 | 4 Filing | 2026-02-13 | English | ||
| 31749645 | 8-K Filing | 2026-02-13 | English | ||
| 13219850 | Regulatory Filings 2026 | 2026-01-20 | English | ||
| 13219851 | CURRENT REPORT | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13219852 | Director's Dealing 2025 | 2025-12-20 | English | ||
| 13219853 | Director's Dealing 2025 | 2025-12-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
OS Therapies Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34454/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34454 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34454 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34454 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34454}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OS Therapies Inc (id: 34454)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.